281 related articles for article (PubMed ID: 32575843)
1. Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.
Gmeiner WH
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575843
[TBL] [Abstract][Full Text] [Related]
2. Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.
Gmeiner WH; Dominijanni A; Haber AO; Ghiraldeli LP; Caudell DL; D'Agostino R; Pasche BC; Smith TL; Deng Z; Kiren S; Mani C; Palle K; Brody JR
Mol Cancer Ther; 2021 Mar; 20(3):553-563. PubMed ID: 33361273
[TBL] [Abstract][Full Text] [Related]
3. Therapy for advanced colorectal cancer.
Benson AB
Semin Oncol; 1998 Oct; 25(5 Suppl 11):2-11. PubMed ID: 9786311
[TBL] [Abstract][Full Text] [Related]
4. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects.
Gmeiner WH; Okechukwu CC
Cancer Drug Resist; 2023; 6(2):257-272. PubMed ID: 37457133
[TBL] [Abstract][Full Text] [Related]
5. Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.
Mani C; Pai S; Papke CM; Palle K; Gmeiner WH
Neoplasia; 2018 Dec; 20(12):1236-1245. PubMed ID: 30439567
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10.
Gmeiner WH; Miller LD; Chou JW; Dominijanni A; Mutkus L; Marini F; Ruiz J; Dotson T; Thomas KW; Parks G; Bellinger CR
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32224870
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model.
Okechukwu CC; Ma X; Sah N; Mani C; Palle K; Gmeiner WH
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611037
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Johnston PG; Mick R; Recant W; Behan KA; Dolan ME; Ratain MJ; Beckmann E; Weichselbaum RR; Allegra CJ; Vokes EE
J Natl Cancer Inst; 1997 Feb; 89(4):308-13. PubMed ID: 9048835
[TBL] [Abstract][Full Text] [Related]
11. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
[TBL] [Abstract][Full Text] [Related]
12. Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway.
Liu H; Liu H; Zhou Z; Parise RA; Chu E; Schmitz JC
Cell Commun Signal; 2018 Feb; 16(1):7. PubMed ID: 29458395
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Cui S
Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
[TBL] [Abstract][Full Text] [Related]
14. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.
Dominijanni A; Gmeiner WH
Cancer Drug Resist; 2018; 1():48-58. PubMed ID: 30613833
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
Du C; Huang D; Peng Y; Yao Y; Zhao Y; Yang Y; Wang H; Cao L; Zhu WG; Gu J
Cancer Lett; 2017 Aug; 400():183-193. PubMed ID: 28465257
[TBL] [Abstract][Full Text] [Related]
16. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
[TBL] [Abstract][Full Text] [Related]
17. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
18. Current status of clinical studies for colorectal cancer in Taiwan.
Chen LT; Whang-Peng J
Clin Colorectal Cancer; 2004 Sep; 4(3):196-203. PubMed ID: 15377403
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.
Libra M; Navolanic PM; Talamini R; Cecchin E; Sartor F; Tumolo S; Masier S; Travali S; Boiocchi M; Toffoli G
BMC Cancer; 2004 Mar; 4():11. PubMed ID: 15040806
[TBL] [Abstract][Full Text] [Related]
20. DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Leon LG; Giovannetti E; Smid K; van Houte BP; Hanauske AR; Giaccone G; Peters GJ
Curr Drug Metab; 2011 Dec; 12(10):956-65. PubMed ID: 21787269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
